Clinical trials: Venetoclax
Acute Myeloid Leukemia
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
- Trial name
- NCT04628026
- Testing
- Venetoclax, Standard chemotherapy, Allogeneic stem cell transplantation
- Where
- 91 sites in Austria, Belgium and 6 more
- Volunteers
- 650 people
- Sponsor
- University of Ulm
Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
This study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment…
- Trial name
- HVA-MPAL (NCT07517510)
- Testing
- HVA
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Guangdong Second Provincial General Hospital
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed).
- Trial name
- NCT04905810
- Testing
- Azacitidine, Decitabine, Venetoclax
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Brian Jonas
Chronic Lymphocytic Leukemia
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice
A study to assess the real-life management and use of healthcare resources during the initiation of: Venetoclax in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia…
- Trial name
- DEVOTE (NCT03310190)
- Where
- 13 sites in Canada
- Volunteers
- 93 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia.
- Trial name
- NCT03701282
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 865 sites in United States, Israel
- Volunteers
- 720 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
This trial seeked to extend the preliminary findings of efficacy by evaluating MBG453 in combination with hypomethylating agents (HMA) and also Bcl-2 inhibitor venetoclax.
- Trial name
- STIMULUS-AML1 (NCT04150029)
- Testing
- MBG453, Venetoclax, Azacitidine
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 90 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
- Trial name
- NCT05564390
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice
- Where
- 360 sites in United States, Canada and 1 more
- Volunteers
- 2,000 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukaemia (AML), Leukemia
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp.
- Conditions
- Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
- Trial name
- NCT07148180
- Testing
- Tagraxofusp, Azacitidine (AZA), Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Jacqueline Garcia, MD
Chronic Lymphocytic Leukemia, CLL
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) following a…
- Conditions
- Chronic Lymphocytic Leukemia, CLL, Relapsed CLL, Refractory Chronic Lymphocytic Leukemia
- Trial name
- RIVe-CLL/SLL (NCT03639324)
- Testing
- Dose combination 1-1, dose combination 1-2, Dose combination 1-3
- Sponsor
- Virginia Commonwealth University
Amyloidosis; Systemic, AL Amyloidosis
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%.
- Trial name
- NCT06192979
- Testing
- Daratumumab, Bortezomib, Dexamethasone
- Where
- 7 sites in China
- Volunteers
- 41 people
- Sponsor
- Jin Lu, MD
Myeloproliferative Neoplasm
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
This phase I trial studies the side effects and best dose of pacritinib when given together with venetoclax and azacitidine in treating patients with accelerated and blast phase myeloproliferative neoplasms (MPN-AP/BP).
- Trial name
- NCT07679334
- Testing
- Pacritinib, Venetoclax, Azacitidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Myeloid, Acute
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid Leukemia (AML) and newly diagnosed AML.
- Trial name
- OMNIVERSE (NCT04887857)
- Testing
- CC-486, Venetoclax
- Where
- 10 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Celgene
Acute Myeloid Leukemia (AML)
Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia
The goal of this clinical trial is to test a way of delivering supportive care to adults 60 years and older who are starting venetoclax-based treatment for newly diagnosed acute myeloid leukemia (AML).
- Trial name
- ACTIVE DEFAULT (NCT07777471)
- Testing
- Active Default
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with a pediatric-inspired chemotherapy regimen known as C10403 in treating patients with newly diagnosed B cell acute lymphoblastic…
- Trial name
- NCT05157971
- Testing
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
This research is being done to study the efficacy and safety of unrelated umbilical cord blood stem cell microtransplantation combined with azacitidine(AZA) based treatment for advanced myelodysplastic syndromes(MDS), Chronic…
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia
- Trial name
- NCT05584761
- Testing
- unrelated umbilical cord blood
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Venetoclax and ibrutinib have complementary activity in clearing the disease across anatomical compartments. By combining ibrutinib with venetoclax, cells can be mobilized from tissues into the bloodstream by ibrutinib and killed…
- Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia
- Trial name
- NCT03708003
- Testing
- Ibrutinib, Venetoclax
- Where
- 11 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Swiss Cancer Institute
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
This phase II MyeloMATCH treatment substudy tests the addition of olutasidenib to usual treatment in patients with higher-risk myelodysplastic syndrome (MDS) or patients with acute myeloid leukemia (AML) with a mutation in the…
- Trial name
- NCT07153497
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT05600894
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 34 sites in United States, Canada
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This phase II trial tests the effect of venetoclax in combination with standard of care (SOC) zanubrutinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT07734038
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Kerry Rogers
Acute Myeloid Leukemia
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
This is a Phase Ib Study to determine the Maximum Tolerated Dose (MTD) of Venetoclax in combination with Gemtuzumab Ozogamicin(GO) in subjects with relapsed/refractory acute myeloid leukemia.
- Trial name
- NCT04070768
- Testing
- Gemtuzumab Ozogamicin, Venetoclax
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- John Quigley